Targets and results

Target 2012

Collaborate with key patient groups to spur government and employer action on COPD early diagnosis and treatment. Collaborate with MS groups to improve standards of diagnosis and management of MS. Advocate for, and provide better training for, diabetes nurses. Follow up on agreed actions to consolidate global advocacy initiative for gout patients.

Result 2012

The “COPD Uncovered” survey, supported by the COPD Foundation (patient group), Education for Health (nurse organization) and IHPM (employer organization), was used to increase awareness among policymakers.

The European MS Patient Group helped coordinate MS Nurse PRO, a nurse training curriculum for the EU.

Following a diabetes nurse training workshop chaired by IDF Europe, outcomes were shared during an EU diabetic macular edema symposium at the Foundation of European Nurses in Diabetes (FEND).

Held first advisory board for gout patient advocacy groups seeking support for better access to new treatments.

Target 2012

Complete rollout of Coartem and Coartem Dispersible under phase one of AMFm. Further expand access to Coartem and Coartem Dispersible in selected malaria endemic countries.

Improve Arogya Parivar supply chain efficiency for remote villages by appointing direct distributors. Support development of local healthcare infrastructure by expanding Credit for Healthcare Initiative.

Result 2012

More than 95 million Coartem treatments, including 55 million Coartem Dispersible treatments, were provided to the public sector and under Phase I of AMFm. Access to Coartem and Coartem Dispersible was further expanded in the private sector in nine select malaria-endemic countries.

80 Arogya Parivar cells (30%) have direct distributors serviced from Novartis India warehouses, improving services and availability of medicines in remote areas. Due to local policy and structural changes in the microfinance sector in India, this initiative was delayed. It has regained momentum since Q3 of 2012 and sign-off is expected in early 2013.

Target 2012

Enter Phase IIa proof-of-concept (POC) with KAE609 (formerly NITD609) and Phase I with KAF156.

Develop process for vaccine for nontyphoidal salmonella. Pilot scale GMP manufacture of Shigella vaccine.

Result 2012

Antimalaria spiroindolone compound KAE609 successfully completed clinical POC, Phase II clinical testing against Plasmodium falciparum and vivax malaria is underway. Antimalaria imidazolopiperazine compound KAF156, active against liver- and blood-stage malaria, was tested in humans and Phase I clinical testing (POC) was initiated. Lab scale process was developed for nontyphoidal salmonella vaccine; in preclinical studies, prototype showed activity against the two main serotypes in Africa. Pilot scale GMP production process was developed for Shigella vaccine and GMP bulk antigen was produced by late 2012.

Target 2012

Build consensus within the Human Rights Working Group around the meaning of the two Human Rights principles for the pharmaceutical sector, and continue to support the Global Compact Office in establishing its LEADership initiative.

Result 2012

Helped work out position paper for the Rio+20 conference on Strategic investments and Philanthropy. Helped define and develop a Board Engagement program on the Global Compact and the Leadership Blueprint.

Target 2012

Support the Local Network Switzerland particularly regarding human rights themes and participate in the World Economic Forum's Global Agenda Council on Human Rights.

Target 2012

Continue using established process to update living wage levels annually and adjust associate salaries that are below those levels.

Result 2012

Completed wage-level review. No employees below the Living Wage were identified.

Target 2012

Global Employee Survey to be administered in March 2013 to include new Alcon associates. We will communicate results and identify focus areas based on employee data, develop action plans, and begin implementation at global, local and functional levels. This third cycle will allow us to continue to be able to compare our results to historical benchmarks.

Result 2012

Stemming from 2011 survey results, actions were taken at local, regional, divisional and global levels. Globally, we established ChangeEx across Novartis. This methodology allows us to give consistent attention to change management through frameworks and tools to increase the successful outcome of change initiatives. Using ChangeEx, Pharmaceuticals established a governance team, workstreams, forums and advocates to drive key change projects. Other feedback we received in 2011 was that we did not acknowledge success well enough. This led NIBR to redesign its Rewards & Recognition program to recognize associates in drug discovery who model its values. We have launched several other initiatives in the areas of development and communications. For example, Vaccines and Diagnostics is now working to help managers better understand how their leadership style affects their teams, while Sandoz is helping front-line managers improve their skills in engaging with shop floor workers. Animal Health has also developed new tools to communicate more effectively across cultures. These are just highlights of what has been done since the last GES; we have implemented many more actions.

Target 2012

Focus on embedding inclusive behaviors. Further integrate D&I into business processes. Implement aligned group and divisional D&I strategy actions.

Result 2012

Inclusive leadership and/or unconscious bias training implemented in five Divisions. D&I integrated into several business processes and programs, including business reviews, marketing plans, as well as the inclusion of diverse populations in research and development programs. The Diversity & Inclusion Advisory Council has been reconfigured in late 2012 to provide strategic direction on the future of work as it relates to D&I at Novartis.

Target 2012

In 2012, we will expand the Be Healthy initiative to 100 additional sites and reach approximately 95% of affiliates' associates. (new target)

Result 2012

The Be Healthy initiative, first introduced in 2011, expanded to include 100 new sites in 2012, reaching 95% of Novartis Group company associates worldwide. Be Healthy supports associates to take care of their health by promoting healthy behaviors and by providing access to analysis of key metrics.

Target 2012

Sustain 2011 performance of Novartis Group without former Alcon and improve Alcon performance by 13% based on 2011; 0.19 including Alcon.

Result 2012

Novartis Group LTIR including Alcon: 0.14. Alcon improved by 49%.

Result 2012

Novartis Group TRCR including Alcon improved by 27% compared to 2011. Alcon improved by 34%.

Target 2012

Improve by a further 15% by 2015, based on 2010.

Result 2012

11% improvement on the 2010 baseline.

Target 2012

Improve by a further 4% by 2012, based on 2010.

Result 2012

6.3% improvement on the 2010 baseline.

Target 2012

Improve by 15% by 2012, based on 2008.

Result 2012

53% reduction compared to the 2008 baseline.

Target 2012

Improve by 15% by 2012, based on 2008.

Result 2012

44% reduction compared to the 2008 baseline.

Target 2012

Decrease to 5% below 1990 level of 308 kilotons by 2012, including carbon offsets.

Result 2012

6.5% reduction compared to the 1990 baseline, including 116ktCO2e from carbon offset projects.

Target 2012

Decrease by 10% by 2015 based on 2010.

Result 2012

19% reduction compared to the 2010 baseline.

Target 2012

Improve efficiency of hazardous waste not recycled by 10% by 2012, based on 2008.

Result 2012

3.8% improvement on the 2008 baseline.

Target 2012

Improve efficiency of non-hazardous waste not recycled by 20% by 2012, based on 2008.

Result 2012

23% improvement on the 2008 baseline.

Target 2012

Reduce total GHG emissions by 15% by 2015 and 20% by 2020, including carbon offsets, based on 2008.

Result 2012

6.8% reduction compared to the 2008 baseline.

Target 2012

Release 2011 UNGC Communication on Progress. Release 2011 Novartis GRI report at a high application level. Consistently update online CSR communications.

Result 2012

2011 UNGC Communication on Progress released in March 2012. Novartis 2011 GRI report received application level A+.

Target 2012

Continue to identify and publish Novartis positions on key healthcare issues.

Result 2012

Published new or expanded Novartis positions on key topics (Biosimilar Pathways, Responsible Substitution, Pharmaceuticals in the Environment). Supported major international, US and European trade associations (total of USD 25 mio).

Target 2012

Strive to maintain high ratings in key industry corporate citizenship rankings.

Target 2012

Rollout Code of Conduct training globally. Expand certification for all associates globally and for all levels. Rollout and train the revised Anti-Bribery Policy. Increase systematic compliance monitoring (new target).

Result 2012

Novartis completed the rollout of the Code of Conduct to all Group company associates in 2012, supported by local Code of Conduct awareness campaigns. All associates received a hard copy of the Code of Conduct, which was translated into over 20 languages. In addition, all 100’477 associates with email access were invited to an e-training and certification, of which 98’175 had completed by 31 December 2012. Face-to-face trainings have been conducted in parallel for associates without email access.

Target 2012

Enhance skill-building for Compliance Officers. Leverage Country Compliance Heads role to drive basic cross-divisional alignment and synergies at the local levels (new target).

Result 2012

Novartis Compliance Officers participated in dedicated live training in Anti-Bribery due diligence and conducting investigations of misconduct.

Country Compliance Heads increased their coordination and facilitation of local, cross-divisional collaboration and alignment, including the rollout of the Code of Conduct, and the systematic sharing of best practices across Divisions.

Target 2012

The new Responsible Procurement Program is approved and implemented. Set up global training program for all impacted associates and third parties. First capability building project with target group of suppliers.

Result 2012

Responsible Procurement (RP) Program has been approved and rolled out on a phased basis to high-risk regions including China and Latin America where new Responsible Procurement Managers were put in place. 250 affected procurement associates have been trained face to face and via webinar, and materials have been developed for them to use when communicating with third parties. A capability project is underway with Chinese construction suppliers working on a major Novartis project.

Target 2012

Promote and monitor best animal welfare practices and compliance internally and at third party providers, based on the Novartis Animal Welfare Policy, Standards and Standard Operating Procedures. Continuous risk assessment of internal animal experiments and third party providers. Integration of Alcon into the Global Novartis Animal Welfare Organization.

Result 2012

Novartis Animal Welfare Policy revised including further controls on use of non-human primates and strengthened compliance procedures. Alcon integration complete with no overall increase in animal numbers across the Novartis Group.